

**Proponent Testimony of Dr. Walter Jerry Mysiw  
on HB 96  
before the Ohio House Health Committee  
March 5, 2025**

Chair Schmidt, Vice Chair Deeter, Ranking Member Somani and members of the Ohio House Health Committee, thank you for the opportunity to testify today.

My name is Dr. Walter Jerry Mysiw. I have served as the Medical Director of the TBI Rehabilitation Services from 1984 to 2021, the Medical Director of Dodd Rehabilitation Hospital from 2010 to 2021, the Chair of Department of PM&R at Ohio State University from 2013 to 2021 and as the Lead Physician for the eTMS Ohio FDA PTSD trial.

I am here today to testify in support of funding eTMS treatment for use in opioid abuse disorder and to continue the use for PTSD for veterans and first responders. We are asking for an additional \$6 million per year to increase the \$4 million in the Governors budget to \$10 million each year of the biennium for the existing eTMS Ohio program for veterans and first responders. We are also requesting \$15 million per year for inpatient and outpatient substance abuse disorders and an FDA trial to study the effects of eTMS on the general population for substance abuse disorders.

In 2021 I first stood before the legislature to advocate for an EEG guided TMS treatment program for Veterans to treat PTSD. Transcranial magnetic stimulation, or TMS has been around since the 1980's and FDA approved for treatment resistant depression since 2008. What makes EEG guided TMS different is the treatment personalization and the measurable improvements seen in mental health and substance use scales including PCL-5 (PTSD), PHQ-9 (depression), GAD-7 (anxiety), OCS (opioid craving scale) and other gold standard assessments. Dr. Won will go over more details regarding data in the next presentation.

Working with Veterans in 2021, we saw stunning improvements in PTSD, sleep, and other mental health disorders. The funding was then approved to add first responders to the program, and again we've seen the same outcomes. So much so, that we've been approved for phase 2 of the FDA PTSD trial. In 2024, after observing significant improvements in opiate and alcohol craving scales in our patients, the team began to consider leveraging this technology for substance use treatment. JLC Services self-funded an initiative at two inpatient treatment centers to demonstrate that this treatment could effectively address opioid, alcohol, and methamphetamine use in the general public. Those results show a 67% decrease in opioid craving, 89% decrease in alcohol craving, and 72% decrease in fentanyl cravings and a 42% decrease methamphetamine/stimulant craving.

I testified four years ago that the transformation I saw in weeks would have taken traditional medicine years to achieve if ever, and I've never been more adamant that this treatment is vitally important. We are requesting additional funding to expand the eTMS Ohio program to treat more Veterans and first responders, while also seeking new funding to address opioid use disorder and substance use issues. Additionally, conducting an FDA trial to further investigate the impact of this treatment would be crucial.

Thank you again for the opportunity to testify today. I am happy to answer any questions.